Treatment with CDK4/6 inhibitors exerts direct effects on T lymphocyte function in the tumor microenvironment (TME), including a decrease in the proliferative capacity of regulatory T cells and an increase in the activity of effector T cells (36, 37). Here, CDK4 is linked to neoplasm.